Lipocine (LPCN) Shares Down 11.2%

Lipocine Inc (NASDAQ:LPCN) shares traded down 11.2% during mid-day trading on Monday . The company traded as low as $1.55 and last traded at $1.66. 686,752 shares traded hands during trading, a decline of 6% from the average session volume of 733,922 shares. The stock had previously closed at $1.87.

A number of research analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of Lipocine in a research report on Monday, March 11th. LADENBURG THALM/SH SH restated a “buy” rating on shares of Lipocine in a research report on Thursday, January 17th. Finally, ValuEngine upgraded Lipocine from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd.

The company has a quick ratio of 4.63, a current ratio of 4.63 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $39.64 million, a PE ratio of -3.25 and a beta of 0.73.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Wednesday, March 6th. The specialty pharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.02). On average, research analysts expect that Lipocine Inc will post -0.84 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc lifted its holdings in shares of Lipocine by 4.9% in the third quarter. Vanguard Group Inc now owns 747,984 shares of the specialty pharmaceutical company’s stock valued at $1,032,000 after buying an additional 35,000 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Lipocine by 4.9% in the third quarter. Vanguard Group Inc. now owns 747,984 shares of the specialty pharmaceutical company’s stock valued at $1,032,000 after buying an additional 35,000 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Lipocine in the first quarter valued at $256,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Lipocine by 145.8% in the third quarter. JPMorgan Chase & Co. now owns 95,429 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 56,606 shares during the period. Institutional investors own 8.83% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Lipocine (LPCN) Shares Down 11.2%” was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thestockobserver.com/2019/04/17/lipocine-lpcn-shares-down-11-2.html.

About Lipocine (NASDAQ:LPCN)

Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.

Featured Story: What are the benefits of investing in REITs?

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.